{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:46:58Z","timestamp":1789152418463,"version":"build-2803163510"},"reference-count":80,"publisher":"American Society for Clinical Investigation","issue":"2","funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"crossref","award":["CBM.THRTOX.01.10.RC.021"],"award-info":[{"award-number":["CBM.THRTOX.01.10.RC.021"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI093504"],"award-info":[{"award-number":["R01AI093504"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,30]]},"abstract":"<jats:p>\n                    Botulinum neurotoxins (BoNTs) are potent neuroparalytic toxins that cause mortality through respiratory paralysis. The approved medical countermeasure for BoNT poisoning is infusion of antitoxin immunoglobulins. However, antitoxins have poor therapeutic efficacy in symptomatic patients; thus, there is an urgent need for treatments that reduce the need for artificial ventilation. We report that the US Food and Drug Administration\u2013approved potassium channel blocker 3,4-diaminopyridine (3,4-DAP) reverses respiratory depression and neuromuscular weakness in murine models of acute and chronic botulism. In ex vivo studies, 3,4-DAP restored end-plate potentials and twitch contractions of diaphragms isolated from mice at terminal stages of BoNT serotype A (BoNT\/A) botulism. In vivo, human-equivalent doses of 3,4-DAP reversed signs of severe respiratory depression and restored mobility in BoNT\/A-intoxicated mice at terminal stages of respiratory collapse. Multiple-dosing administration of 3,4-DAP improved respiration and extended survival at up to 5 LD\n                    <jats:sub>50<\/jats:sub>\n                    BoNT\/A. Finally, 3,4-DAP reduced gastrocnemius muscle paralysis and reversed respiratory depression in sublethal models of serotype A\u2013, B\u2013, and E\u2013induced botulism. These findings make a compelling argument for repurposing 3,4-DAP to symptomatically treat symptoms of muscle paralysis caused by botulism, independent of serotype. Furthermore, they suggest that 3,4-DAP is effective for a range of botulism symptoms at clinically relevant time points.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.132891","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T11:01:11Z","timestamp":1580295671000},"source":"Crossref","is-referenced-by-count":23,"title":["Symptomatic treatment of botulism with a clinically approved small molecule"],"prefix":"10.1172","volume":"5","author":[{"given":"Edwin","family":"Vazquez-Cintron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Machamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celinia","family":"Ondeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Pagarigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Winner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Bodner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ross","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.116.012658"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.44.101802.121554"},{"issue":"1","key":"B3","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9010038","article-title":"Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature","volume":"9","author":"Peck","year":"2017","journal-title":"Toxins (Basel)"},{"issue":"6","key":"B4","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10060231","article-title":"Engineering of Botulinum Neurotoxins for Biomedical Applications","volume":"10","author":"Webb","year":"2018","journal-title":"Toxins (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1123654"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200305098"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2008.11.018"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1949.sp004364"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1086\/444507"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.2.298-314.2006"},{"issue":"suppl_1","key":"B11","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/cid\/cix815","article-title":"Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016","volume":"66","author":"O\u2019Horo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B12"},{"issue":"suppl_1","key":"B13","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/cid\/cix816","article-title":"Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin","volume":"66","author":"Yu","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1086\/518890"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2013.02.014"},{"key":"B16","article-title":"Botulinum Neurotoxins as Biothreat Agents","volume":"S2","author":"Smith","year":"2012","journal-title":"Journal of Bioterrorism and Biodefense"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0022-5193(79)90141-3"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90988-4"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000336354"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.10.035"},{"key":"B21"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(77)90037-5"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvoice.2014.04.010"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2018.01.012"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(86)90133-X"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1021\/cb1002366"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(99)00231-7"},{"issue":"1","key":"B28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","article-title":"Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.L118.005425"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/BF00586516"},{"issue":"6","key":"B31","first-page":"691","article-title":"Use of ion channel blockers in studying the regulation of skeletal muscle contractions","volume":"344","author":"Lin-Shiau","year":"1991","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"B32","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005637","article-title":"Synaptic vesicle exocytosis","volume":"3","author":"S\u00fcdhof","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"B33","first-page":"445","article-title":"[Effect of 4-aminopyridine on the development of experimental botulism]","volume":"100","author":"Morrison","year":"1985","journal-title":"Biull Eksp Biol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2007.05529.x"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(87)90166-8"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1039\/C6CC00615A"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/cc12880"},{"issue":"7-8","key":"B38","first-page":"379","article-title":"Human type A botulism and treatment with 3,4-diaminopyridine","volume":"32","author":"Davis","year":"1992","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.52.3.858-862.1986"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(95)00127-1"},{"issue":"13","key":"B41","first-page":"601","article-title":"[Treatment of severe botulism with 3,4-diaminopyridine]]","volume":"31","author":"Dock","year":"2002","journal-title":"Presse Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16064-3"},{"key":"B43","unstructured":"CDC. National Botulism Surveillance. http:\/\/www.cdc.gov\/nationalsurveillance\/botulism-surveillance.html"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186892"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112599"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.4.334"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12218"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.99"},{"issue":"2","key":"B49","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","article-title":"Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome","volume":"88","author":"Lundh","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"B50","first-page":"96","article-title":"Standardized assay for Clostridium botulinum toxins","volume":"61","author":"Schantz","year":"1978","journal-title":"Journal of the Association of Official Analytical Chemists"},{"issue":"8","key":"B51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2621.2005.tb11525.x","article-title":"Methods for Detecting Botulinum Toxin with Applicability to Screening Foods Against Biological Terrorist Attacks","volume":"70","author":"Scarlatos","year":"2005","journal-title":"J Food Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198910000-00015"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806006169"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2018.00080","article-title":"Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance","volume":"6","author":"Thirunavukkarasu","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006567"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063191"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(94)00183-9"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.606222"},{"issue":"191","key":"B60","first-page":"473","article-title":"Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak","volume":"48","author":"Ball","year":"1979","journal-title":"Q J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010992200"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00152.x"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.1065","article-title":"The destructive effect of botulinum neurotoxins on the SNARE protein: SNAP-25 and synaptic membrane fusion","volume":"3","author":"Lu","year":"2015","journal-title":"PeerJ"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.52.36897"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2905-14.2015"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2017.10.017"},{"issue":"8","key":"B67","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10080313","article-title":"Botulinum Toxin Induced Atrophy: An Uncharted Territory","volume":"10","author":"Salari","year":"2018","journal-title":"Toxins (Basel)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051926"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11022.x"},{"key":"B70","first-page":"341","article-title":"Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine","volume":"7","author":"Lindquist","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.05.353"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1994.1181"},{"key":"B73","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-13-127","article-title":"High yield derivation of enriched glutamatergic neurons from suspension-cultured mouse ESCs for neurotoxicology research","volume":"13","author":"Hubbard","year":"2012","journal-title":"BMC Neurosci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(01)00101-5"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2013.05.004"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0209-y"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/BF01117450"},{"issue":"16","key":"B79","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1016\/S0021-9258(17)39364-X","article-title":"Conus geographus toxins that discriminate between neuronal and muscle sodium channels","volume":"260","author":"Cruz","year":"1985","journal-title":"J Biol Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1981.sp013586"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/132891\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:19:29Z","timestamp":1779193169000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/132891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":80,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1,30]]},"published-print":{"date-parts":[[2020,1,30]]}},"alternative-id":["10.1172\/jci.insight.132891"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.132891","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"article-number":"e132891"}}